Skip to main content
Premium Trial:

Request an Annual Quote

MediGene Licenses Gene Regulation System From Valentis

NEW YORK, May 20-Valentis said today that it has licensed its GeneSwitch gene regulation technology to the German drug developer MediGene.


MediGene will have the rights to use this technology for research purposes, in exchange for an immediate payment and annual maintenance fees.


The companies did not disclose financial details of the agreement.


Valentis' technology allows researchers to regulate the expression of certain genes in transgenic animals and cell cultures, a process useful in gene function identification and target validation.

This is the sixth non-exclusive license that the Burlingame, Calif.-based company has granted to pharmaceutical and biotechnology partners since February 2001.


MediGene, a publicly traded company that focuses on cancer drug development, is based in Martinsreid, with a U.S. subsidiary in San Diego, Calif.


For additional information about the deal, click here.

The Scan

Genes Linked to White-Tailed Jackrabbits' Winter Coat Color Change

Climate change, the researchers noted in Science, may lead to camouflage mismatch and increase predation of white-tailed jackrabbits.

Adenine Base Editor Targets SCID Mutation in New Study

Researchers from the University of California, Los Angeles, report in Cell that adenine base editing was able to produce functional T lymphocytes in a model of severe combined immune deficiency.

Researchers Find Gene Affecting Alkaline Sensitivity in Plants

Researchers from the Chinese Academy of Science have found a locus affecting alkaline-salinity sensitivity, which could aid in efforts to improve crop productivity, as they report in Science.

International Team Proposes Checklist for Returning Genomic Research Results

Researchers in the European Journal of Human Genetics present a checklist to guide the return of genomic research results to study participants.